Hybrigenics SA has announced that it has received the second €800,000 installment of a €1.4 million loan from France’s innovation agency OSEO after the successful completion of a Phase IIa clinical study of its oral inecalcitol, a treatment in hormone-refractory prostate cancer patients.
The first payment of €600,000 was received at the signature of the contract in 2008.
“This is a highly significant grant for Hybrigenics. It shows Oseo’s confidence in our product and in our ability to successfully complete clinical trials,” said Guillaume Floch, Hybrigenics’ CFO.
The interest-free loan from OSEO must be repaid between 2012 and 2015. “This second payment will help fund further clinical development of inecalcitol.” Floch said.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
